A Phase I, Open-label, Single-center, Crossover Design of Food-effect Study of SH-1028 Tablets in Healthy Subjects
Latest Information Update: 04 May 2021
At a glance
- Drugs Rilertinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Nanjing Sanhome Pharmaceutical
Most Recent Events
- 07 Jun 2019 New trial record